Completed OBSERVATIONAL NCT00004091

Detection of Biomarkers in Abnormal Cervical Cells in Women With Abnormal Pap Test Results

Development of Antibody-Based Diagnostic Markers for Abnormal Cervical Cells

Sponsor: National Cancer Institute (NCI)

Interventions Papanicolaou test colposcopic biopsy cytology specimen collection procedure fluorescent antibody technique study of high risk factors

Updated 6 times since 2017 Last updated: Jan 27, 2011 Started: Aug 31, 1999 Primary completion: Feb 28, 2001 Completion: Feb 28, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00004091, this observational or N/A phase trial focuses on Cervical Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Aug 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Northwestern University

Data source: Northwestern University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States